PH12018501331A1 - Crystalline forms of thienopyrimidine compound - Google Patents

Crystalline forms of thienopyrimidine compound

Info

Publication number
PH12018501331A1
PH12018501331A1 PH12018501331A PH12018501331A PH12018501331A1 PH 12018501331 A1 PH12018501331 A1 PH 12018501331A1 PH 12018501331 A PH12018501331 A PH 12018501331A PH 12018501331 A PH12018501331 A PH 12018501331A PH 12018501331 A1 PH12018501331 A1 PH 12018501331A1
Authority
PH
Philippines
Prior art keywords
crystalline forms
thienopyrimidine compound
same
thienopyrimidine
compound
Prior art date
Application number
PH12018501331A
Inventor
Jae Hyuk Jung
Jong Ouk Baek
Sun Young Jung
Eun Joo Kwak
Hee Cheol Kim
Tae Hee Ha
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of PH12018501331A1 publication Critical patent/PH12018501331A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present invention relates to crystalline forms of N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)thieno[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide, and pharmaceutical compositions containing the same. The crystalline forms can be easily used for the preparation of a pharmaceutical composition containing the same as an active ingredient.
PH12018501331A 2015-12-31 2018-06-21 Crystalline forms of thienopyrimidine compound PH12018501331A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150190854 2015-12-31
PCT/KR2016/015536 WO2017116193A1 (en) 2015-12-31 2016-12-30 Crystalline forms of thienopyrimidine compound

Publications (1)

Publication Number Publication Date
PH12018501331A1 true PH12018501331A1 (en) 2019-02-18

Family

ID=59225209

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12018501331A PH12018501331A1 (en) 2015-12-31 2018-06-21 Crystalline forms of thienopyrimidine compound

Country Status (16)

Country Link
US (1) US10464946B2 (en)
EP (1) EP3380482A4 (en)
JP (1) JP2019504046A (en)
KR (1) KR20180089904A (en)
CN (1) CN108473507A (en)
AU (1) AU2016382385A1 (en)
BR (1) BR112018013364A2 (en)
CA (1) CA3010315A1 (en)
HK (1) HK1252842A1 (en)
IL (1) IL259982A (en)
MX (1) MX2018008005A (en)
PH (1) PH12018501331A1 (en)
RU (1) RU2018122825A (en)
SG (1) SG11201804860YA (en)
TW (1) TW201726686A (en)
WO (1) WO2017116193A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170050453A (en) * 2015-10-30 2017-05-11 한미약품 주식회사 Novel process for preparing thienopyrimidine compound and intermediates used therein
EP3380481A4 (en) * 2015-12-31 2019-05-15 Hanmi Pharm. Co., Ltd. CRYSTALLINE FORMS OF CHLOROHYDRATE SALTS OF A THIENOPYRIMIDINE COMPOUND
KR102819183B1 (en) * 2019-03-29 2025-06-13 한미약품 주식회사 Crystalline forms of acid addition salts of furopyrimidine compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX342164B (en) 2010-06-23 2016-09-19 Hanmi Science Co Ltd Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity.
WO2015112705A2 (en) 2014-01-24 2015-07-30 Clovis Oncology, Inc. Therapeutic combinations for treating cancer
TW201622744A (en) * 2014-03-04 2016-07-01 美國禮來大藥廠 Combination therapy for cancer
WO2016025641A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and an egfr inhibitor and related methods
JP2018502081A (en) * 2014-12-30 2018-01-25 ハンミ ファーマシューティカルズ カンパニー リミテッド Novel production method of thienopyrimidine compound and intermediate used therefor
KR20170050453A (en) * 2015-10-30 2017-05-11 한미약품 주식회사 Novel process for preparing thienopyrimidine compound and intermediates used therein

Also Published As

Publication number Publication date
US20190016733A1 (en) 2019-01-17
KR20180089904A (en) 2018-08-09
RU2018122825A3 (en) 2020-02-28
IL259982A (en) 2018-07-31
AU2016382385A1 (en) 2018-07-12
BR112018013364A2 (en) 2018-12-04
EP3380482A4 (en) 2019-05-15
MX2018008005A (en) 2019-03-14
SG11201804860YA (en) 2018-07-30
JP2019504046A (en) 2019-02-14
US10464946B2 (en) 2019-11-05
CN108473507A (en) 2018-08-31
TW201726686A (en) 2017-08-01
CA3010315A1 (en) 2017-07-06
EP3380482A1 (en) 2018-10-03
HK1252842A1 (en) 2019-06-06
WO2017116193A1 (en) 2017-07-06
RU2018122825A (en) 2020-02-04

Similar Documents

Publication Publication Date Title
MX2021015106A (en) Novel ferroportin inhibitors.
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
TN2016000081A1 (en) Aminoheteroaryl benzamides as kinase inhibitors
MY210123A (en) Tlr7/8 antagonists and uses thereof
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201691242A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING AZD9291
NZ716840A (en) Combination formulation of two antiviral compounds
NZ631112A (en) Crystalline bromodomain inhibitors
PH12016502461A1 (en) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts
PH12018501643A1 (en) Tlr7 agonist crystalline form a, preparation method and use thereof
MX2021002256A (en) Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt.
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
MX2015014025A (en) Novel n-(2,3-dihydro-1h-pyrrolo[2,3-b]jpyrid in-5-yl)-4- quinazolinamine and n-(2,3-dihydro-1h-i ndol-5-yl)-4- quinazolinamine derivatives as perk inhibitors.
MX379558B (en) New crystalline form of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
MX2019012454A (en) Novel crystalline solid compound of 3-phenyl-4-propyl-1-(pyridin- 2-yl)-1h-pyrazol-5-ol hydrochloride.
EP4295916A3 (en) Salts of 4-amino-n-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and crystalline forms thereof
PH12018501331A1 (en) Crystalline forms of thienopyrimidine compound
MX2015016429A (en) Cxcr7 receptor modulators.
PH12018501314A1 (en) Crystalline forms of hydrochloride salts of thienopyrimidine compound
ZA202107890B (en) Crystal form of acid addition salt of puropyrimidine compound
NZ728660A (en) A tetrahydropyrrolo[3,4-d][1,3]thiazine-derivative as bace inhibitor
IN2013MU02366A (en)